-
MG-262 for Proteasome Assays in Muscle Research
2026-09-27
Use MG-262 to perturb ubiquitin–proteasome activity while keeping it experimentally distinct from chaperone-mediated autophagy (CMA). This guide outlines cell-based workflows, practical controls and interpretation limits for muscle-proteostasis studies, apoptosis research and cell cycle arrest studies.
-
Ang II–HIF-1α-HILPDA Axis and NPC Radioresistance
2026-09-26
The study links locally produced angiotensin II (Ang II) to reduced ferroptosis and increased radioresistance in nasopharyngeal carcinoma (NPC), identifying an AGT–HIF-1α–HILPDA feedback axis. Its results support testing Ang II blockade alongside ferroptosis-inducing approaches, while the proposed mechanism and treatment implications require further validation.
-
How In Vitro Assays Separate Cancer Drug Effects
2026-09-26
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central finding—that many drugs influence both proliferation and cell death, but to different extents and on different timelines—supports using measurements that distinguish growth arrest from actual cell killing.
-
Demethyleneberberine: Decoding the Mitochondrial IL-1β Axis
2026-09-25
Demethyleneberberine (DMB) offers a way to investigate how TLR4-driven mitochondrial changes connect inflammatory priming to mature IL-1β release. This article explains the key experimental insight behind that model and how to design assays that distinguish pathway stages rather than treating inflammation as a single endpoint.
-
Brassinolide Analogs with C-22 Benzyl Groups
2026-09-25
This study synthesizes seven brassinosteroid analogs bearing benzyl groups at C-22 and compares their plant-growth activity in the rice lamina inclination test. Its central structure–activity finding is that benzyl substitution alone is not sufficient: activity depends on aromatic substitution and its position, with the para-fluoro analog markedly outperforming its benzoylated comparator.
-
Ruxolitinib phosphate in Reliable Cell Assays
2026-09-24
Learn how to use Ruxolitinib phosphate (SKU A3781) to investigate JAK/STAT signaling in viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers assay design, preparation, interpretation, and practical criteria for selecting a research reagent.
-
Wnt-C59 Workflows for PORCN-Dependent Wnt Research
2026-09-24
Use Wnt-C59 to test whether a phenotype depends on PORCN-mediated Wnt secretion, from TCF reporter assays to cancer-cell studies. A carefully bounded extension links this approach to lithium-engineered BMSC exosomes while distinguishing established findings from experiments that still need validation.
-
Pexidartinib (PLX3397) CSF1R Research Workflow
2026-09-23
Build a controlled CSF1R perturbation workflow for macrophage-rich tumor models, osteoclast studies, and hypothesis-driven neuroimmune assays. This guide combines stock-preparation guidance, dose-response design, reference-study translation, and troubleshooting for more interpretable Pexidartinib experiments.
-
Methicillin Sodium Salt in MSSA Research
2026-09-22
Methicillin sodium salt provides a practical benchmark for MSSA susceptibility testing, PBP-focused mechanism studies, and gram-positive bacterial infection models. This guide shows how to build reproducible dilution workflows, distinguish MSSA activity from mecA-mediated resistance, and translate endpoint discipline from a modern antibacterial trial into bench assays.
-
Metabolic Sensitization of Ferroptosis and Cuproptosis
2026-09-22
This 2024 Chemical Engineering Journal study presents SCu/L, a copper–tannic acid network/liposome system that encapsulates STF-31 to inhibit glycolysis and compensatory NAD+ metabolism. By lowering metabolic and antioxidant defenses while limiting copper export, the strategy strengthens ferroptosis and cuproptosis and also improves antitumor immune activity.
-
Sex Differences in Angiotensin II Hypertension
2026-09-21
Xue and colleagues used telemetry in conscious, freely moving mice to show that chronic angiotensin II produces a substantially greater pressor response in males than in females. Gonadectomy, baroreflex testing, and ganglionic blockade connected this phenotype to sex-hormone effects, autonomic regulation, and sex-specific adaptation of cardiovascular reflexes.
-
Camptothecin Workflows for DNA Damage Research
2026-09-21
Build reproducible Camptothecin experiments around a defined topoisomerase I lesion, from DMSO stock preparation and γH2AX profiling to autophagy and adaptation assays. The workflow connects acute DNA damage with longer-term genome-stability questions while separating validated product biology from exploratory evolutionary interpretations.
-
Thymoquinone Cardiotoxicity Research Workflow
2026-09-20
Build a reproducible Thymoquinone workflow for doxorubicin-induced cardiac injury, from solvent preparation through ferroptosis, oxidative-stress, and mitochondrial readouts. The approach translates mouse evidence into practical assay decisions while clearly separating validated findings from exploratory optimization.
-
Protease Inhibitor Cocktail for MS-Safe Extraction
2026-09-19
Protect fragile protein targets during cold extraction, pH-shift experiments, and MS-based proteomics with a broad-spectrum, AEBSF-free formulation. This guide translates recent Lassa virus spike research into practical sample-handling, assay-design, and troubleshooting decisions.
-
QX77 Molecular Chaperone Activator Workflow
2026-09-19
QX77 enables controlled studies of LAMP2A-linked chaperone-mediated autophagy, Rab11 trafficking, and embryonic stem-cell differentiation in one experimental toolkit. This workflow separates direct compound responses from the ETS1–SENP2–HSPA8/FUNDC1 mitophagy mechanism reported in hyperoxia-induced lung injury.